SPOTLIGHT -
Dr. Norden on Cost and Effectiveness of Genomic Testing
Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.
Read More
Dr. Norden on Differences Between mCODE and Cota's CNA Network
Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
